Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Article Views are the COUNTER-compliant sum of full text article downloads since ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is making headlines after its Phase 3 ROSELLA trial showed relacorilant, combined with nab-paclitaxel, reduced disease progression risk by 30% in ...

A simple white box with an innocuous door which opens unsuspectingly to gnarling rows of switches, each marked in hieroglyphics: “MCB1”, “ELCB ... had 2 of their 3 kids all by himself. “ ...

SRM Institute of Science and Technology has released the SRMJEEE 2025 phase two schedule. Online registration concludes on June 6, 2025. The exam will be online. It will be for two and a half hours.

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy to show ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis ...

Regeneron Pharmaceuticals and Sanofi announced that their Phase 3 clinical trial, AERIFY-1, showed a significant 27% reduction in moderate to severe exacerbations of COPD in former smokers treated ...

JD.com’s stablecoin is in Phase 2 of Hong Kong’s sandbox testing. The token is pegged to fiat currencies and built for cross-border and retail transactions. JD Chain CEO Liu Peng warned against ...

YONGIN, South Korea, May 30, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its ...

AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically ...

Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea (OSA). AD109 is a once daily pill that consists of ...

Roche announced the phase 3 trial will be a single pivotal study with approximately 400 patients from around the world, randomised to receive either zosuarbalpin or the standard treatment.